Stephens JM. RIFL aims to be a new player in lipid metabolism.
A RECENT DISCOVERY by Ren et al. (4) describes the expression of a gene in liver and adipose tissue in a variety of model systems that suggests a potentially important role in lipid metabolism. These authors have named the gene RIFL. RIFL is an acronym for refeeding induced in fat and liver. The discovery of RIFL can be attributed to both experimental and in silico approaches. In short, the results of transcriptional profiling from an adipogenesis experiment in 3T3-L1 cells were used to select genes that had an at least 10-fold higher expression in adipocytes compared with preadipocytes. Genes that met this criteria were analyzed to evaluate tissue-specific expression profiles with the BioGPS database (7) . Next, these genes were also analyzed using a null mouse model phenotype database for transmembrane and secreted proteins (5) . Candidate genes were further considered if the null mouse indicated a defect in metabolism. Collectively, the use of an initial experimental approach followed by two database analyses led to the investigation of a murine gene that had never been studied. Remarkably, there have been no publications on the RIFL gene, transcript, or protein in any species.
The current article "Identification of RIFL, a novel adipocyteenriched insulin target gene with a role in lipid metabolism" (4) has likely identified a gene that will be the subject of much future research. In this study, it was observed that RIFL expression is highly induced during adipocyte differentiation in a variety of rodent and human model systems. Some evidence suggests that RIFL may be a peroxisome proliferator-activated receptor-␥ (PPAR␥) target gene, but this idea is based solely on data showing that PPAR␥ knockdown cells have less RIFL expression. However, the loss of RIFL expression substantially attenuates lipid accumulation in 3T3-L1 cells. The ability of this gene product to modulate lipid accumulation is likely to be tissue specific since the study also revealed a significant enrichment of RIFL mRNA expression in white adipose tissue (WAT), brown adipose tissue (BAT), and liver. The overall majority of RIFL in adipose tissue is present in the adipocytes. An evaluation of the stromovasular portion of adipose tissue suggests that RIFL is not expressed in the variety of other cell types that are present in fat. In humans, RIFL expression is also highly enriched in liver and fat. A striking feature of RIFL expression is that it is highly nutritionally regulated. In both WAT and liver, RIFL is nearly undetectable during fasting and highly induced by refeeding. RIFL mRNA expression is also elevated significantly in the liver and WAT of ob/ob mice. In addition, RIFL expression is induced by insulin in a time-and dose-dependent manner. However, these studies did not determine which of the multiple insulin-signaling pathways played a role in the induction of RIFL. Additional studies did reveal that various agents that promote lipolysis inhibit RIFL gene expression. Other genes, including PPAR␥ (6) and fatty acid synthase (3), exhibit similar patterns of regulation and are important players in lipid metabolism. Moreover, most genes that are regulated by fasting and refeeding in the liver are known to play a role in lipid or fatty acid metabolism (8) .
Future studies on RIFL will likely include an analysis of lipid metabolism and insulin action in the null mice and generation of liver-and fat-specific knockouts to evaluate its importance in WAT, BAT, and liver. RIFL protein sequence lacks substantial sequence homologies, structural domains, or motifs that are indicative of enzymatic activity. Preliminary analysis also indicates a strong likelihood of a signal peptide. Together, these data suggest that RIFL may function as a secreted factor. fibroblast growth factor 21 is another secreted factor that is generated in liver, WAT, and other tissues that has generated a lot of interest for its antiobesity and antidiabetic properties (1, 2) . A notable deficiency in the study of secreted factors is whether the functions are mediated by autocrine, paracrine, or endocrine signaling. Although the functions of RIFL have not been determined, there is compelling evidence demonstrating substantial nutritional regulation of this gene and significant enrichment in adipose tissue and liver. These observations, coupled with data showing that RIFL knockdown in adipocytes is associated with less lipid accumulation and that RIFL-null mice have serum triacylglycerol levels that are one-third that of wild-type mice, strongly suggest that RIFL is a new important player in lipid metabolism.
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